News | February 21, 2023
Teijin and Axcelead to establish drug discovery research JV
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
The new sterile filling line meets cGMP aseptic filling regulatory requirements
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Cipla has received 8 inspectional observations in Form 483
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
Subscribe To Our Newsletter & Stay Updated
